August 4, 2020
FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant Glioma Bookmark
Press release from Oncoceutics curated by Executive Director Erika Vial Monteverdi.
The U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the drug ONC201 for treating a type of brain tumor known as “H3 K27M-mutant glioma,” which is primarily found in children. Alongside the Musella Foundation For Brain Tumor Research & Information, Inc, and the company xCures, Cancer Commons has been supporting this program to help patients in need.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.